Background The androgen receptor (AR) remains a critical driver in metastatic castration-
resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Background Plasma tumor DNA fraction is prognostic in metastatic cancers. This could
improve risk stratification before commencing a new treatment. We hypothesized that a …

Background Androgen receptor (AR) ligand-binding domain (LBD) mutations occur in~ 20%
of all castration-resistant prostate cancer (CRPC) patients. These mutations confer ligand …

ABSTRACT Introduction: Prostate cancer (PCa) is one of the most common malignancies in
men and a major cause of cancer deaths among men worldwide. Prostate specific antigen …

In recent years, new therapeutic options have become available for prostate cancer (PC)
patients, generating an urgent need for better biomarkers to guide the choice of therapy and …

Context Genomic testing is becoming increasingly important in patients with advanced
prostate cancer (PC) and is being incorporated in clinical practice to guide treatment …

The androgen receptor drives the growth of metastatic castration-resistant prostate cancer.
This has led to the development of multiple novel drugs targeting this hormone-regulated …

Prostate cancer is one of the most frequent cancers in men and is a common cause of
cancer-related death. Despite significant progress in the diagnosis and treatment of this …

The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly
expanded. There is a need to develop noninvasive biomarkers to guide treatment. We …